Across TCGA pan-cancer cohorts, SESN2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SESN2’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where SESN2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SESN2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.
LUAD and CCRCC are the cancer types where SESN2 tumor–normal differential expression is most reproducible.